Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: Comparison with a human specimen

Journal of Neurochemistry

Volumn 134, Issue 6, 2015, Pages 1104-1115

  Uchida, Yasuo ^a   Zhang, Zhengyu ^a   Tachikawa, Masanori ^a   Terasaki, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

blood cerebrospinal fluid barrier; human rat difference; MATE1; oatp1a5; PEPT2; protein expression level

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; GLUCOSE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER F; PEPTIDE TRANSPORTER 2; PROTEIN MDR1A; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CELL MEMBRANE; CHOROID PLEXUS; CONTROLLED STUDY; FRACTIONATION; HUMAN; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; PROTEOMICS; QUANTITATIVE ANALYSIS; RAT; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; LIQUID CHROMATOGRAPHY; METABOLISM; TANDEM MASS SPECTROMETRY; WISTAR RAT;

ANIMALS; BLOOD-BRAIN BARRIER; CHOROID PLEXUS; CHROMATOGRAPHY, LIQUID; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; PROTEOMICS; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY;

EID: 84941809505     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13147     Document Type: Article

References (51)

1. Ahn J., Beharry S., Molday L. L., and, Molday R. S., (2003) Functional interaction between the two halves of the photoreceptor-specific ATP binding cassette protein ABCR (ABCA4). Evidence for a non-exchangeable ADP in the first nucleotide binding domain. J. Biol. Chem. 278, 39600-39608.
2. Asaba H., Hosoya K., Takanaga H., Ohtsuki S., Tamura E., Takizawa T., and, Terasaki T., (2000) Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J. Neurochem. 75, 1907-1916.
3. Bhongsatiern J., Ohtsuki S., Tachikawa M., Hori S., and, Terasaki T., (2005) Retinal-specific ATP-binding cassette transporter (ABCR/ABCA4) is expressed at the choroid plexus in rat brain. J. Neurochem. 92, 1277-1280.
4. Cattori V., van Montfoort J. E., Stieger B., Landmann L., Meijer D. K., Winterhalter K. H., Meier P. J., and, Hagenbuch B., (2001) Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 443, 188-195.
5. Ci L., Kusuhara H., Adachi M., Schuetz J. D., Takeuchi K., and, Sugiyama Y., (2007) Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol. Pharmacol. 71, 1591-1597.
6. Duan H., and, Wang J., (2013) Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene. J. Biol. Chem. 288, 3535-3544.
7. Dyer J., Barker P. J., and, Shirazi-Beechey S. P., (1997) Nutrient regulation of the intestinal Na+/glucose co-transporter (SGLT1) gene expression. Biochem. Biophys. Res. Commun. 230, 624-629.
8. Friden M., Winiwarter S., Jerndal G., Bengtsson O., Wan H., Bredberg U., Hammarlund-Udenaes M., and, Antonsson M., (2009) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J. Med. Chem. 52, 6233-6243.
9. Gideon P., Thomsen C., Stahlberg F., and, Henriksen O., (1994) Cerebrospinal fluid production and dynamics in normal aging: a MRI phase-mapping study. Acta Neurol. Scand. 89, 362-366.
10. Hoshi Y., Uchida Y., Tachikawa M., Inoue T., Ohtsuki S., and, Terasaki T., (2013) Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci. 102, 3343-3355.
11. Hu Y., Shen H., Keep R. F., and, Smith D. E., (2007) Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J. Neurochem. 103, 2058-2065.
12. Kamiie J., Ohtsuki S., Iwase R., et al., (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res. 25, 1469-1483.
13. Kanai N., Lu R., Satriano J. A., Bao Y., Wolkoff A. W., and, Schuster V. L., (1995) Identification and characterization of a prostaglandin transporter. Science 268, 866-869.
14. Keep R. F., and, Smith D. E., (2011) Choroid plexus transport: gene deletion studies. Fluids Barriers CNS 8, 26.
15. Kitazawa T., Hosoya K., Takahashi T., Sugiyama Y., and, Terasaki T., (2000) In-vivo and in-vitro evidence of a carrier-mediated efflux transport system for oestrone-3-sulphate across the blood-cerebrospinal fluid barrier. J. Pharm. Pharmacol. 52, 281-288.
16. Kodaira H., Kusuhara H., Fujita T., Ushiki J., Fuse E., and, Sugiyama Y., (2011) Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J. Pharmacol. Exp. Ther. 339, 935-944.
17. Kuroda M., Kusuhara H., Endou H., and, Sugiyama Y., (2005) Rapid elimination of cefaclor from the cerebrospinal fluid is mediated by a benzylpenicillin-sensitive mechanism distinct from organic anion transporter 3. J. Pharmacol. Exp. Ther. 314, 855-861.
18. Kusuhara H., and, Sugiyama Y., (2004) Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv. Drug Deliv. Rev. 56, 1741-1763.
19. Lindberg R. L., Martini R., Baumgartner M., et al., (1999) Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J. Clin. Invest. 103, 1127-1134.
20. Liu C. B., Wang R., Dong M. W., Gao X. R., and, Yu F., (2014) Amyloid-beta transporter expression at the choroid plexus in normal aging: the possibility of reduced resistance to oxidative stress insults. Sheng Li Xue Bao 66, 158-168.
21. Luckner P., and, Brandsch M., (2005) Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur. J. Pharm. Biopharm. 59, 17-24.
22. Muller W. E., and, Snyder S. H., (1977) delta-Aminolevulinic acid: influences on synaptic GABA receptor binding may explain CNS symptoms of porphyria. Ann. Neurol. 2, 340-342.
23. Nakanishi T., and, Tamai I., (2014) Putative roles of organic anion transporting polypeptides (OATPs) in cell survival and progression of human cancers. Biopharm. Drug Dispos. 35, 463-484.
24. Ohtsuki S., Asaba H., Takanaga H., Deguchi T., Hosoya K., Otagiri M., and, Terasaki T., (2002) Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J. Neurochem. 83, 57-66.
25. Ohtsuki S., Uchida Y., Kubo Y., and, Terasaki T., (2011) Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J. Pharm. Sci. 100, 3547-3559.
26. Ohtsuki S., Schaefer O., Kawakami H., et al., (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40, 83-92.
27. Ohtsuki S., Ikeda C., Uchida Y., et al., (2013) Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol. Pharm. 10, 289-296.
28. Otsuka M., Matsumoto T., Morimoto R., Arioka S., Omote H., and, Moriyama Y., (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl Acad. Sci. USA 102, 17923-17928.
29. Radford D. J., Wang K., McNelis J. C., Taylor A. E., Hechenberger G., Hofmann J., Chahal H., Arlt W., and, Lord J. M., (2010) Dehydroepiandrosterone sulfate directly activates protein kinase C-beta to increase human neutrophil superoxide generation. Mol. Endocrinol. 24, 813-821.
30. Rolinson G. N., and, Sutherland R., (1965) The binding of antibiotics to serum proteins. Br. J. Pharmacol. Chemother 25, 638-650.
31. Rousselle C., Clair P., Temsamani J., and, Scherrmann J. M., (2002) Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. J. Drug Target. 10, 309-315.
32. Shawahna R., Uchida Y., Decleves X., et al., (2011) Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 8, 1332-1341.
33. Shen H., Smith D. E., Keep R. F., and, Brosius F. C., 3rd, (2004) Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol. Pharm. 1, 248-256.
34. Smith D. E., Hu Y., Shen H., Nagaraja T. N., Fenstermacher J. D., and, Keep R. F., (2011) Distribution of glycylsarcosine and cefadroxil among cerebrospinal fluid, choroid plexus, and brain parenchyma after intracerebroventricular injection is markedly different between wild-type and Pept2 null mice. J. Cereb. Blood Flow Metab. 31, 250-261.
35. Spector R., and, Johanson C. E., (2010) Vectorial ligand transport through mammalian choroid plexus. Pharm. Res. 27, 2054-2062.
36. Strazielle N., and, Ghersi-Egea J. F., (2000) Choroid plexus in the central nervous system: biology and physiopathology. J. Neuropathol. Exp. Neurol. 59, 561-574.
37. Sullivan G. M., Hatterer J. A., Herbert J., et al., (1999) Low levels of transthyretin in the CSF of depressed patients. Am. J. Psychiatry 156, 710-715.
38. Tachibana T., Kitamura S., Kato M., Mitsui T., Shirasaka Y., Yamashita S., and, Sugiyama Y., (2010) Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm. Res. 27, 442-446.
39. Tachikawa M., Kasai Y., Takahashi M., Fujinawa J., Kitaichi K., Terasaki T., and, Hosoya K., (2008) The blood-cerebrospinal fluid barrier is a major pathway of cerebral creatinine clearance: involvement of transporter-mediated process. J. Neurochem. 107, 432-442.
40. Tachikawa M., Ozeki G., Higuchi T., Akanuma S., Tsuji K., and, Hosoya K., (2012) Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin E(2) produced in the brain. J. Neurochem. 123, 750-760.
41. Tanihara Y., Masuda S., Sato T., Katsura T., Ogawa O., and, Inui K., (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem. Pharmacol. 74, 359-371.
42. Terada T., Masuda S., Asaka J., Tsuda M., Katsura T., and, Inui K., (2006) Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm. Res. 23, 1696-1701.
43. Tsuruoka S., Ishibashi K., Yamamoto H., Wakaumi M., Suzuki M., Schwartz G. J., Imai M., and, Fujimura A., (2002) Functional analysis of ABCA8, a new drug transporter. Biochem. Biophys. Res. Commun. 298, 41-45.
44. Uchida Y., Kamiie J., Ohtsuki S., and, Terasaki T., (2007) Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm. Res. 24, 2281-2296.
45. Uchida Y., Ohtsuki S., Katsukura Y., Ikeda C., Suzuki T., Kamiie J., and, Terasaki T., (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117, 333-345.
46. Uchida Y., Tachikawa M., Obuchi W., Hoshi Y., Tomioka Y., Ohtsuki S., and, Terasaki T., (2013) A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 10, 21.
47. Uchida Y., Wakayama K., Ohtsuki S., Chiba M., Ohe T., Ishii Y., and, Terasaki T., (2014) Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 350, 578-588.
48. Williams A. C., and, Ramsden D. B., (2005) Autotoxicity, methylation and a road to the prevention of Parkinson's disease. J. Clin. Neurosci. 12, 6-11.
49. Williams M. J., Lowrie M. B., Bennett J. P., Firth J. A., and, Clark P., (2005) Cadherin-10 is a novel blood-brain barrier adhesion molecule in human and mouse. Brain Res. 1058, 62-72.
50. Yee S. W., Nguyen A. N., Brown C., et al., (2013) Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J. Pharm. Sci. 102, 3451-3457.
51. Zhong M., Molday L. L., and, Molday R. S., (2009) Role of the C terminus of the photoreceptor ABCA4 transporter in protein folding, function, and retinal degenerative diseases. J. Biol. Chem. 284, 3640-3649.